V09GA02 - Technetium (99mTc) Tetrofosmin |
Propably not porphyrinogenic |
PNP |
Rationale
Technetium (99mTc) tetrofosmin is administered in low dose and the therapeutic plasma concentration is considered to be insignificant in relation to having potentially porphyrinogenic effects.
Metabolism and pharmakokinetics
After administration, technetium (99mTc) tetrofosmin is rapidly distributed and has a high affinity for myocardial and skeletal muscle (Higley 1993).
According to Schreuder and coworkers, the plasma concentration of technetium (99mTc) tetrofosmin is 0.07µM and the hepatic load is therefore probably insignificant (Shcreuder 2016).
Approximately 66% of the injected activity is excreted within 48 hours post-injection, with approximately 40% excreted in the urine and 26% in the feces (FDA label).
No dug-drug interactions are listed in interaction databases (Lexicomp, Micromedex).
References
- Scientific articles
- Higley B, Smith FW et al. Technetium-99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993 Jan;34(1):30-8. PMID 8418268. #2972
- Schreuder N, Mamedova I et al. Radiopharmaceuticals in Acute Porphyria. Clin Ther. 2016 Oct;38(10):2239-2247. PMID 27568214. #4727
- Government bodies
- U.S. Food and Drug Administration (FDA). Label information: Myoview. (updated: April 2017). #2974
- Drug interaction databases
- Lexi-Interact, via UpToDate. #1152
- Micromedex® 2.0 (online). Drug Interactions). (23.08.2017). #1411
Similar drugs
© NAPOS 2024